KIM Jin - soo, Director of the IBS Center for Genome Editing and corresponding author of the two studies commented, «Since the two studies have proved the superior specificity of Cpf1,
this new nuclease will be more widely used for precise genome editing that does not produce any unintended mutations.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for
new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger
nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit
new drug applications for
new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for
new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Talk of curing AIDS made front - page news last year, in part due to an astonishing
new gene - editing technology: lab - engineered proteins called zinc finger
nucleases.
In it, they sound the alarm about
new genome - editing techniques known as CRISPR and zinc - finger
nucleases that make it much easier for scientists to delete, add, or change specific genes.
Compounding this risk, the liver cells that now contain the DNA for ZFNs will keep making the
nucleases for perhaps years, even though they are no longer needed to guide the
new gene to its spot in the genome.
The adaptation of xenopus model to
new technologies such as customized
nucleases and automated screening tools, enables a wider use of the amphibian model.
The variety of
new tools available for genetic manipulation now include lentiviral - based gene delivery, and gene editing using CRISPR / Cas9, zinc finger
nucleases (ZFNs) or transcription activator - like effector
nucleases (TALENs).
Live at IMG Marie - Christine Birling, PHENOMIN - ICS, France Title: «Genome editing using
nucleases:
new possibilities and application to reveal gene function in diseases»
Ultimately this will include the expanding repertoire of advanced technologies such as clustered regularly interspaced short palindromic repeats (CRISPR), CRISPR - associated protein 9 (Cas9), and zinc - finger
nucleases (ZFNs)(46) along with the
new clinical indications and markets that they address.
Two
newer gene - editing methods — zinc finger
nucleases, used since the late 1990s, and TALENs, first described in 2011 — allowed more precise modifications, he says, «but there was a real art and skill required, and only a handful of labs could do those.»